This page is available in multiple languages
EnterNext welcomes TxCell on Euronext's market in Paris
Damian Marron, CEO of TxCell, opens the European trading day in Paris.
TxCell is a biotechnology group that specializes in developing customized cell immunotherapy using antigen-specific regulatory T cells (Ag-Tregs) and for the treatment of severe chronic inflammatory and autoimmune diseases.
At the end of 2013, TxCell has a portfolio of 4 products including 1 in phase II of development (Ovasave; treatment of the Crohn disease), 1 in phase I/II of development (Col-Treg; treatment of autoimmune uveitis), 1 in phase of preclinical development (Myelin-Treg; treatment of the progressive forms of multiple sclerosis) and 1 in research phase (HSP60-Treg).